Universal tumor antigens as targets for immunotherapy

Cytotherapy

Volumn 4, Issue 4, 2002, Pages 317-327

  Gordan, J D ^a   Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CYP IBI; hTERT; MDM 2; Telomerase, survivin

Indexed keywords

CYTOCHROME P450 1B1; CYTOKINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN TELOMERASE RNA DIRECTED DNA POLYMERASE; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; MELAN A; MONOPHENOL MONOOXYGENASE; PEPTIDE; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; SURVIVIN; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR ANTIGEN NY ESO 1; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; BIOINFORMATICS; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CELL SELECTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG TARGETING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN GENOME; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TECHNIQUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE NEU; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR REJECTION; VACCINATION;

EID: 0036384891     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402760271091     Document Type: Article

References (87)

1. Van den Eynde B, Lethe B, Van Pel A et al. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991;173:1373-84.
2. Shankaran V, Ikeda H, Bruce AT et al. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
3. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-7.
4. Altman JD, Moss PAH, Goulder PJR et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
5. Romero P, Cerottini J-C, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today 1998;4:305-12.
6. Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Curr Opin Immunol 2001;13:141-6.
7. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
8. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
9. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-16.
10. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70.
11. Jager E, Ringhoffer M, Altmannsberger M et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71:142-7.
12. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-6.
13. Maeurer MJ, Gollin SM, Storkus WJ et al. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 1996;2:641-52.
14. Sherman LA, Theobald M, Morgan D et al. Strategies for tumor elimination by cytotoxic T lymphocytes. Crit Rev Immunol 1998;18:47-54.
15. Gjertsen MK, Bakka A, Breivik J et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995;346:1399-1400.
16. Jaeger E, Bernhard H, Romero P et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-9.
17. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic Immunol 1998;18:47-54.
18. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
19. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
20. Gjertsen MK, Buanes T, Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50.
21. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
22. Lau R, Wang F, Jeffery G et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24:66-78.
23. Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001;7:2277-84.
24. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-7.
25. Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001;167:7150-6.
26. Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
27. Yee C, Thompson JA, Roche P et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T-cell-mediated vitiligo. J Exp Med 2000;192:1637-44.
28. + T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-42.
29. Pittet MJ, Valmori D, Dunbar PR et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-15.
30. Zippelius A, Pittet MJ, Batard P et al. Thymic selection generates a large T-cell pool recognizing a self-peptide in humans. J Exp Med 2002;166:7634-40.
31. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
32. Sanders DS, Kerr MA. Lewis blood group and CEA related antigens; coexpressed cell-cell adhesion molecules with roles in the biological progression and dissemination of tumours. Mol Pathol 1999;52:174-8.
33. Van den Eynde BJ, van der Bruggen P. T-cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
34. Jungbluth AA, Chen YT, Stockert E et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-60.
35. Haffner AC, Tassis A, Zepter K et al. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer 2002;97:668-70.
36. Stockert E, Jager E, Chen YT et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
37. Jungbluth AA, Stockert E, Chen YT et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000;83:493-7.
38. Offringa R, Vierboom MP, van der Burg SH et al. p53: a potential target antigen for immunotherapy of cancer. Ann NY Acad Sci ??;910:223-33.
39. Theobald M, Biggs J, Hernandez J et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-41.
40. Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self-tolerance on the TCR repertoire. J Immunol 2000;164:596-602.
41. Nikitina EY, Clark JI, Van Beynen J et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001;7:127-35.
42. Umano Y, Tsunoda T, Tanaka H et al. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001;84:1052-7.
43. Theobald M, Ruppert T, Kuckelkorn U et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998;188:1017-28.
44. Minamoto T, Mai M, Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers - a review. Cancer Detect Prev 2000;24:1-12.
45. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-6.
46. + T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72:784-90.
47. Hunger RE, Brand CU, Streit M et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol 2001;10:161-7.
48. Gjertsen MK, Gaudernack G. Mutated Ras peptides as vaccines in immunotherapy of cancer. Vox Sang 1998;74:489-95.
49. Shepard HM, Lewis GD, Sarup JC et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11:117-27.
50. Perez EA. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. Curr Oncol Rep 2001;3:516-22.
51. Disis L, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 1998;18:37-45.
52. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84.
53. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 2001;22:516-23.
54. Strausberg RL, Greenhut SF, Grouse LH et al. In silico analysis of cancer through the Cancer Genome Anatomy Project. Trends Cell Biol 2001;11:S66-S71.
55. Maecker B, Sherr D-H, Shen C et al. Targeting universal tumor antigens with cytotoxic T cells: potential of CYP1B1 for broadly applicable antigen-specific immunotherapy. Blood 1999;94S:438a.
56. Romero P, Dunbar PR, Valmori D et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-50.
57. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
58. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002;21:674-9.
59. Kim NW, Piatyszek MA, Prowse KR et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-15.
60. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
61. Ramakrishnan S, Eppenberger U, Mueller H et al. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998;58:622-5.
62. Hahn WC, Counter CM, Lundberg AS et al. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
63. Hahn WC, Stewart SA, Brooks MW et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-70.
64. Herbert B, Pitts AE, Baker SI et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999;96:14276-81.
65. Zhang X, Mar V, Zhou W et al. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999;13:2388-99.
66. Harle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 1996;93:6476-81.
67. Kolquist KA, Ellisen LW, Counter CM et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998;19:182-6.
68. Norrback KF, Roos G. Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 1997;33:774-80.
69. Yasumoto S, Kunimura C, Kikuchi K et al. Telomerase activity in normal human epithelial cells. Oncogene 1996; 13:433-9.
70. Minev B, Hipp J, Firat H et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000;97:4796-801.
71. Vonderheide RH, Anderson KS, Hahn WC et al. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001;7:3343-8.
72. Nair SK, Heiser A, Boczkowski D et al. Induction of cytotoxic T lymphocyte responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-17.
73. Vonderheide RH, Domchek SM, Hahn WC et al. Vaccination of cancer patients against telomerase: a phase I study using peptide-pulsed dendritic cells Blood 2001; 98S:508a.
74. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
75. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4.
76. Velculescu VE, Madden SL, Zhang L et al. Analysis of human transcriptomes. Nat Genet 1999;23:387-8.
77. Li F, Ackermann EJ, Bennett CF et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999;1:461-6.
78. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001;98:635-40.
79. Rohayem J, Diestelkoetter P, Weigle B et al. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000;60:1815-17.
80. Andersen MH, Pedersen LO, Capeller B et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61:5964-8.
81. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001;61:869-72.
82. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60:4845-9.
83. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
84. Deb SP. Function and dysfunction of the human oncoprotein MDM2. Front Biosci 2002;7:d235-243.
85. Kaminsky LS, Spivack SD. Cytochromes P450 and cancer. Mol Aspects Med 1999;20:70-84, 137.
86. Murray GI, Taylor MC, McFayden MC et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026-31.
87. DeLeo AB, Jay G, Appella E et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979;76:2420-4.